Xilio Therapeutics (XLO) Profit After Tax (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Profit After Tax data on file, last reported at -$9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 28.16% year-over-year to -$9.5 million; the trailing twelve-month figure through Mar 2026 stood at -$31.3 million (up 42.36% YoY), and the FY2025 full-year result was -$35.0 million, up 39.84% from the prior year.
• Profit After Tax retreated to -$9.5 million in Q1 2026, from $10.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $10.4 million in Q4 2025 to a low of -$24.6 million in Q2 2022.
• A 5-year average of -$15.7 million and a median of -$16.7 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax declined 28.12% in 2022 and surged 179.13% in 2025, its largest moves.
• Tracing XLO's Profit After Tax over 5 years: stood at -$22.4 million in 2022, then climbed by 21.34% to -$17.7 million in 2023, then climbed by 25.84% to -$13.1 million in 2024, then surged by 179.13% to $10.4 million in 2025, then plunged by 191.98% to -$9.5 million in 2026.
• Business Quant data shows XLO's Profit After Tax at -$9.5 million in Q1 2026, $10.4 million in Q4 2025, and -$16.3 million in Q3 2025.